Lowering of blood pressure by chronic suppression of central sympathetic outflow: Insight from prolonged baroreflex activation

Journal of Applied Physiology

Volumn 113, Issue 10, 2012, Pages 1652-1658

  Lohmeier, Thomas E ^a   Iliescu, Radu ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; ANIMAL; ARTERIAL PRESSURE; CAROTID SINUS; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG RESISTANCE; ELECTROSTIMULATION THERAPY; HUMAN; HYPERTENSION; INNERVATION; KIDNEY; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BAROREFLEX; CAROTID SINUS; CENTRAL NERVOUS SYSTEM; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84867542067     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00552.2012     Document Type: Review

References (32)

1. Bie P. Blood volume, blood pressure and total body sodium: Internal signalling and output control. Acta Physiol (Oxf) 195: 187-196, 2009.
2. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the doubleblind, randomized, placebo-controlled Rheos Pivotal trial. J Am Coll Cardiol 58: 765-773, 2011.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica A, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension diagnosis evaluation, treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51: 1403-1419, 2008.
4. Chapleau MW, Hajduczok G, Abboud FM. Resetting of the arterial baroreflex: Peripheral and central mechanisms. In: Reflex Control of the Circulation, edited by Zucker IH and Gilmore JP. Boca Raton, FL: CRC, 1991, p. 165-194.
5. Cowley AW Jr. Long-term control of arterial pressure. Physiol Rev 72: 231-300, 1992.
6. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 77: 75-197, 1997. (Pubitemid 27069290)
7. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48: 787-796, 2006. (Pubitemid 44610980)
8. Guyton AC, Coleman TC, Granger HJ Circulation: overall regulation. Annu Rev Physiol 34: 13-46, 1972.
9. Guyton AC. Arterial pressure and hypertension. Philadelphia: Saunders, 1980.
10. Hall JE, da Silva AA, Brandon E, Stec DE, Ying Z, Jones DW. Pathophysiology of obesity-induced hypertension and target organ damage. In: Comprehensive Hypertension, edited by Lip GYH and Hall JE. Philadelphia: Elsevier, 2007, p. 447-468.
11. Hester RL, Brown AJ, Husband L, Iliescu R, Pruett D, Summers R, Coleman TG. HumMod: A modeling environment for the simulation of integrative human physiology. Frontiers Physiol 2: 1-12, 2011.
12. Iliescu R, Lohmeier TE. Lowering of blood pressure during chronic suppression of central sympathetic outflow: Insight from computer simulations. Clin Exptl Pharmacol Physiol 37: E24-33, 2010.
13. Iliescu R, Irwin ED, Georgakopoulos D, Lohmeier TE. Renal responses to chronic suppression of central sympathetic outflow. Hypertension 60: 749-756, 2012.
14. Kirchheim HR, Finke R, Hackenthal E, Lowe W, Persson P. Baroreflex sympathetic activation increases threshold pressure for pressuredependent renin release in conscious dogs. Pflügers Arch 405: 127-135, 1985. (Pubitemid 16255601)
15. Lohmeier TE, Carroll RG. Chronic potentiation of vasoconstrictor hypertension by adrenocorticotropic hormone. Hypertension 4, Suppl II: II-138-II-148, 1982.
16. Lohmeier TE, Drummond HA. The baroreflex in the pathogenesis of hypertension. In: Comprehensive Hypertension, edited by Lip GYH and Hall JE. Philadelphia: Elsevier, 2007, p. 265-279.
17. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Sedar DJ, Kieval RS. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 46: 1194-1200, 2005. (Pubitemid 41533025)
18. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, Kieval RS. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 49: 373-379, 2007. (Pubitemid 46143015)
19. Lohmeier TE, Hildebrandt DA, Dwyer TM, Iliescu R, Irwin ED, Cates AW, Rossing MA. Prolonged activation of the baroreflex decrease arterial pressure even during chronic adrenergic blockade. Hypertension 53: 833-838, 2009.
20. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation. Mechanisms and potential for hypertension therapy. Hypertension 57: 880-886, 2011.
21. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol 299: H402-H409, 2010.
22. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59: 331-338, 2012.
23. Lohmeier TE, Irwin ED, Rossing MA, Sedar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 43: 306-311, 2004. (Pubitemid 38174130)
24. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA. Baroreflexes prevent neurally-induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol 279: R1437-R1448, 2000.
25. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular diseases. Physiol Rev 90: 513-557, 2010.
26. Osborn JW, Averina VA, Fink GD. Current computational models do not reveal the importance of the nervous system in long-term control of arterial pressure. Exp Physiol 94: 389-395, 2009.
27. Scheffers IJM, Kroon AA, Schmidli J, Jordan J, Tordoir JJM, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension. J Am Coll Cardiol 56: 1254-1258, 2010.
28. Schillaci G, Pucci G, Parati G. Blood pressure variability. An additional target for antihypertensive treatment? Hypertension 58: 155-160, 2011.
29. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361: 932-934, 2009.
30. Seelinger E, Andersen JL, Bie P, Reinhardt HW. Elevated renal perfusion pressure does not contribute to natriuresis induced by isotonic saline infusion in freely moving dogs. J Physiol 559: 939-951, 2004. (Pubitemid 39276179)
31. Symplicity HTN2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial). Lancet 376: 1903-1909, 2011.
32. Yang HM, Lohmeier TE, Kivlign SD, Carroll RG, Smith MJ Jr. Sustained increases in plasma epinephrine concentration do not modulate renin release. Am J Physiol Endocrinol Metab 257: E57-E64, 1989.